America Read the Warning Label and Took the Drug Anyway

For the first time, a country looked hard at a drug’s risks and chose it anyway. The law was not built for that.

The drug that one in eight American adults is now taking started with a lizard.

In the venom of the Gila monster, a squat desert reptile that eats only a handful of times a year, researchers found a hormone that behaved a lot like one of our own. It governed how the body handled sugar and when it felt full. By 2005, that discovery had become the first of a new class of diabetes drugs. Two decades later, a refined version of the same idea is the molecule inside Ozempic and Wegovy.

Which makes the panic around these drugs a little strange. For a drug surrounded by so much alarm, the GLP-1 class has a long and frankly well-documented pedigree. Semaglutide, the active ingredient, was approved to treat type 2 diabetes in 2017. The weight-loss version arrived in 2021. So when people call this a fad, they are describing the marketing, not the medicine. The hype is new. The chemistry is old.

Then came the lawsuits

What is new is the scale, and the danger ahead. By the middle of 2026, two separate federal court proceedings were sorting through thousands of injury claims against the manufacturers, alleging the drugs cause everything from stomach paralysis to sudden blindness. And none of it slowed anyone down. 

Over roughly the same eighteen months that the lawsuits gathered, the share of American adults taking these drugs doubled, from 6 percent to 12 percent, according to KFF. Gallup, asking separately about weight loss, traced the same climb.

That is not how these stories usually go. A diet drug that is the subject of mass litigation is supposed to collapse. Fen-phen did (this one you might not even remember). This one accelerated straight through its own scare campaign, which points to something the lawsuits cannot explain on their own. For perhaps the first time, a country has looked hard at a drug’s risks, weighed them in plain view, and decided the trade was worth making.

Three things are worth understanding before you decide what to make of that. The drugs work better than the panic admits, which is why the fear cannot get traction. The demand has grown so intense that a shadow supply market has emerged alongside the real one, one that federal regulators have linked to serious adverse events, including deaths. And the whole thing is about to get much bigger, because the needle is about to become a pill. Underneath all of it sits a question a personal injury firm cannot ignore: what happens to the law when tens of millions of people decide a known danger is beside the point?

The drugs work. That’s the problem.

To understand why the warnings bounce off, you have to see what people are getting in return.

In November 2023, a Cleveland Clinic cardiologist named Michael Lincoff stood before the American Heart Association and reported a result no diet drug had ever produced. In a trial of 17,604 patients with obesity and existing heart disease but no diabetes, semaglutide had cut the rate of heart attacks, strokes, and cardiovascular death by 20 percent. In absolute terms, the rate fell from 8 percent to 6.5 percent. It was the first time a weight-loss medication had been shown, in a rigorous trial, to prevent the cardiac events that kill people.

On that basis, the FDA approved Wegovy in 2024 to reduce cardiovascular risk. Other trials produced kidney-protection data. A cousin drug became the first medication ever approved for obstructive sleep apnea.

So the person who stays on the drug through the scare ads is not being reckless. They are making a defensible wager: that a benefit measured in heart attacks avoided outweighs a risk that, for most of them, will never arrive. A great many of them are right. That is the engine of everything that follows, and the reason none of the warnings have managed to slow the line.

The real dangers, and the fake ones

That said, “most of them” is not “all of them,” and the honest version of this story names the risks instead of waving them away.

Several of the early scares have quietly fallen apart. The thyroid-cancer warning traces back to studies in rats; in large human populations the risk did not appear, and the apparent signal turned out to be a quirk of how often patients on the drug get screened. A suicide scare prompted formal reviews on two continents, and regulators found no causal link; the FDA went on to ask manufacturers to drop the warning. Pancreatitis, an early suspect, has not held up across the trial record.

Two risks have. One is a form of sudden, usually permanent vision loss with the unlovely name of nonarteritic anterior ischemic optic neuropathy. It is real, it is rare, and exactly how rare is what competing studies are still fighting about. The other is severe gastroparesis, in which the stomach slows to a near halt. The catch is that slowing the stomach is how these drugs work in the first place. The whole dispute is over how often a deliberate effect tips into a lasting injury, and whether the drug creates the problem or merely exposes one the patient was already heading toward.

For a firm that represents injured people, the uncomfortable truth is that this uncertainty runs both directions. Some claims involve risks the science has not ultimately supported. And the claims that remain, the patients with documented, serious, drug-linked harm, deserve to be taken more seriously for it, because they are no longer lost in the noise.

The lawyers arrive

That is the backdrop against which the legal apparatus is now running at full speed.

The gastrointestinal claims sit in multidistrict litigation in the Eastern District of Pennsylvania, MDL 3094, before Judge Karen Marston. By June 2026, the federal count held 3,763 cases. The vision-loss claims got their own proceeding, MDL 3163, which opened in December 2025 and was assigned to the same judge. 

The plaintiffs say the manufacturers failed to warn patients and doctors about the gastrointestinal dangers. The companies say they warned plenty. Somewhere between the docket and the dinner table, legal advertising around these claims has become its own small industry, reaching potential plaintiffs by symptom: stomach paralysis, vision loss, did you or someone you love.

Now it comes as a pill

And the population about to be exposed is set to grow, because the hardest part of taking these drugs is about to disappear.

The needle is on its way out. Oral versions are arriving: a pill form of semaglutide and a once-daily tablet from Eli Lilly called orforglipron that cleared FDA review this spring. Pills are cheaper to make, simpler to ship, and far easier to start than a weekly injection. The user base is poised to widen again, toward younger people and toward those buying the drug with a fraction of the medical supervision a diabetic gets from an endocrinologist. Whatever the litigation is wrestling with now, it is wrestling with a sliver of the population that will be taking these drugs a few years from now. The scale is about to jump a second time, in the middle of the lawsuits.

You don’t know what’s in the vial

Which leads to the strangest corner of all this, and the one almost nobody is watching.

The hunger for these drugs grew so fierce that a shadow supply sprang up beside the real one. While the brand-name versions were scarce, federal rules briefly let compounding pharmacies make copies, and a sprawling trade of med spas, wellness clinics, and telehealth sites rushed to sell injectable “semaglutide,” often to customers who never sat for anything resembling a real examination.

Then the shortage ended. In 2025, the FDA declared the supply restored, which pulled the legal floor out from under mass compounding. Much of the trade carried on anyway, through a workaround that is equal parts clever and absurd: pharmacies began adding a splash of vitamin B12 to the mix, so they could argue the result was a personalized formulation rather than a copy of the brand. 

By late 2025, according to the research firm IQVIA, more than 80 percent of compounded prescriptions carried an additive like this. The FDA eventually made clear that a semaglutide-plus-B12 shot at a brand-equivalent strength is still essentially a copy, and moved to bar bulk compounding of these drugs outright. A bipartisan group of 38 state attorneys general, California among them, wrote to the agency warning that counterfeit versions were endangering consumers.

This is no longer a story about side effects. It is a story about not knowing what is in the vial. Independent testing of compounded products has turned up doses well off their stated strength. And the FDA’s own adverse-event system logged more than 900 reports of harm tied to compounded versions, including several deaths, through late 2024. Those are reports, not proven causes, and the difference matters. But the silhouette of the thing is hard to miss.

Sit with the whole picture for a moment. 

A country looked at a drug carrying real, litigated risks and reached for it anyway, in numbers that doubled in a year and a half. And some slice of those people wanted it so badly they purchased compounded versions of uncertain strength and composition through online platforms with little to no medical oversight, the demand strong enough to keep a gray market alive after the law tried to close it, a market federal regulators have linked to serious adverse events, including deaths, and still the line at the clinic did not shorten. Indifference would be easier to explain. This is something else: a deliberate, clear-eyed, national decision to accept a risk, made by tens of millions of people at once.

What the law does now

The legal system has no settled answer for that, and you can watch it inventing one.

When Judge Marston ruled in August 2025 that anyone claiming drug-induced gastroparesis had to support the diagnosis with an objective test, a gastric-emptying study, rather than symptoms alone, the easy reading was that she was trimming an overgrown docket. 

The deeper thing she was doing was building a sieve, a way to separate genuine injury from the ordinary letdown of a drug that millions chose with open eyes. The filings kept climbing anyway. But she had drawn a line the older mass torts never had to draw.

Because the central claim in this litigation, failure to warn, rests on a premise that is quietly coming apart. The doctrine is more technical than a single sentence can hold, but its spine is simple: the maker hid a danger, and the patient, left in the dark, was harmed by what they did not know. 

That logic was built for a world where people do not know. It strains in a world where the side effects are a punchline on late-night television, debated across kitchen tables, where one in eight adults ran the math knowingly, and where some of them went hunting for the drug down channels no warning label ever reached, purchasing compounded versions of uncertain strength and composition through online platforms with little to no medical oversight.

The courts will spend years deciding whether these drugs are dangerous. They are litigating a question the public has already closed. America read the label. The rest of us are still catching up to what that means: the lawyers, the regulators, and the judge in Philadelphia drawing fresh lines around a decision the country made without us.

This article was written by DK Law, a personal injury law firm licensed in California. It is intended for informational purposes only and does not constitute legal advice or create an attorney-client relationship.